Search Bar & Filters
Found 35 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
This research aims to collect and evaluate safety and effectiveness information about Jyseleca tablet Filgotinib Maleate 100 mg and 200 mg in Korean participants using it in real-world conditions. The study focuses on monitoring serious and non-serious adverse events and drug reactions, including unexpected ones, as well as changes in disease activity scores related to rheumatoid arthritis and ulcerative colitis. Participants prescribed Jyseleca according to Korean approved therapeutic indications will be observed without additional intervention. They will be followed for up to 24 weeks or until they stop treatment due to adverse events or other reasons. The study includes adults with rheumatoid arthritis or ulcerative colitis who have not responded well or are intolerant to prior treatments. During the study, researchers will track adverse events and reactions from enrollment through 24 weeks. They will also measure changes in disease activity scores at baseline, week 12, and week 24. Participants will have regular monitoring visits as part of their usual care, with data collected about safety and treatment effects. The total participation time is up to 24 weeks.
Actively Recruiting
Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
Actively Recruiting
Healthy Volunteer
This research aims to develop and validate a model that predicts heart function, especially the left ventricular ejection fraction LVEF, by combining echocardiography results with body composition data from the QCCUNIQ BC 720 device. The study focuses on adults with and without heart failure to better understand how body composition relates to heart health and to enhance early detection of cardiac dysfunction. Participants will undergo standard echocardiographic exams to measure heart function and body composition analysis using the QCCUNIQ BC 720 device within one week of their heart scan. The study includes 2,000 adults split evenly between those with normal heart function LVEF 6550% and those with heart failure LVEF below 50%. Researchers will analyze these data using traditional and advanced machine learning methods to create a predictive model. Throughout the study, participants will have their heart function and body composition assessed, with data collected on parameters like fat mass, muscle mass, and total body water. The study will track outcomes such as LVEF within one week and evaluate the models accuracy through statistical validation. The goal is to find a non-invasive method to identify individuals at risk for heart problems, potentially reducing reliance on complex diagnostics and improving personalized care.
Actively Recruiting
Researchers are evaluating the usefulness of an insole-type gait analyzer in adults who experience subjective gait and balance disorders. The study focuses on how well this device collects gait data from patients with walking disturbances, aiming to explore the datas clinical value without using a control group. This trial is sponsored by Yonsei University and includes adults aged 19 and older who report gait or balance issues. Participants will wear the insole-type gait analyzer while performing the Timed Up and Go test, which measures walking speed and balance. Before this, they will complete a history survey, a sarcopenia screening questionnaire, and the International Physical Activity Questionnaire. The insole device records data from accelerometers and pressure sensors to detect missing or unusual readings and to explore optimal data collection and analysis methods. During the study, participants will be assessed through baseline tests including the Timed Up and Go test lasting about 5 minutes, the Korean version of the Sarcopenia Screening Questionnaire about 1 minute, and the Korean version of the International Physical Activity Questionnaire about 3 minutes. Researchers will monitor the quality of data collected from the insole during walking and analyze it for clinical significance. The total participation timeline depends on these assessments and data evaluations.
Actively Recruiting
Researchers are evaluating the combination of atezolizumab and bevacizumab with stereotactic body radiotherapy SBRT for patients with advanced hepatocellular carcinoma. This study aims to improve the treatment response rate of the current first-line chemotherapy, which has shown low response rates. Participants have advanced liver cancer that cannot be operated on and are eligible for this combination therapy. Participants will receive SBRT targeting one to five sites of primary or metastatic cancer lesions within two months before or after starting the atezolizumab-bevacizumab combination therapy. The study includes several visits screening, during and after SBRT, chemotherapy cycles, and follow-up visits lasting up to 36 months to monitor treatment effects and safety. During the study, participants will undergo medical history reviews, physical exams, imaging tests like CT or MRI, blood tests including tumor markers and biomarkers, stool microbiota analysis, and quality of life questionnaires. Researchers will monitor adverse events and assess progression-free survival at 6 months as the primary outcome, alongside secondary outcomes such as overall survival, tumor response, and safety over 36 months.
Actively Recruiting
Researchers are studying patients with end-stage knee osteoarthritis OA to understand how their phase angle level before surgery relates to their recovery after total knee arthroplasty. The study aims to find out if patients with a low phase angle have worse functional recovery compared to those with a high phase angle, and whether preoperative phase angle is linked to postoperative physical function. This observational study compares physical function and muscle strength in these groups to identify associations with recovery outcomes. Participants undergo several assessments before and three months after surgery. The pre-surgical evaluation includes surveys on medical history, sarcopenia, and physical activity. Functional tests include bioelectrical impedance analysis to measure phase angle and body composition, handgrip strength tests, isokinetic knee strength measurement, and performance-based tests such as the 10-meter walk test, Timed Up and Go TUG test, and Berg Balance Scale BBS. Radiographic assessments evaluate knee osteoarthritis severity and alignment. During the study, participants complete the same series of tests at baseline and three months post-surgery to track changes in function and strength. Researchers monitor outcomes like TUG, 10-meter walk, and BBS scores to assess recovery. Muscle strength and phase angle measurements are also recorded at both time points. The total participation spans from preoperative screening through a three-month follow-up after the knee replacement procedure.
Actively Recruiting
Researchers are evaluating the radiation exposure to operators during percutaneous coronary intervention PCI by comparing two different access points the left distal radial artery LDRA and the right conventional radial artery RTRA. This study aims to understand which approach may result in less radiation exposure to the medical personnel performing the procedure. The trial is a multicenter, randomized study sponsored by Yonsei University and focuses on radiation safety during coronary interventions. Participants will undergo PCI using either the left distal radial artery approach or the right radial artery approach. The study compares radiation exposure to the operator measured by dosimeters placed on the left wrist, left head, and left chest during the procedure. The procedures and associated use of fluoroscopy, procedure time, and contrast medium volume are monitored and recorded. This study does not involve any masking or placebo controls and allocates participants randomly to one of the two study groups. During the study, participants will receive PCI as planned with one of the two arterial access methods. Researchers will measure cumulative radiation exposure to the operator and secondary outcomes such as crossover rate, fluoroscopy time, procedure time, and contrast medium volume during and up to 24 hours after the procedure. Participation involves standard PCI procedures with additional radiation monitoring. The study is expected to continue until April 2029, with ongoing assessment of radiation safety outcomes.
1-10 of 35
1